Heart Failure

An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in hospital admission for heart failure.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Dr. Thosani discusses the convergence of technology and physiology, treatment advancements, and virtual medicine capabilities in the field of heart arrhythmia.

These reductions were only observed in short-term follow-up and were driven by early reductions within 12 months of telemedicine intervention.

The mean LDL-C level among US young adults was 104.9 mg/dL In 2015-2020.

A lower SPPB score was associated with greater risk of composite and individual CVD outcomes.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.

Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.

The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.

The scientific statement reviews symptoms associated with ACS, heart failure, valvular disorders, stroke, rhythm disorders, and peripheral vascular disease.

An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

Early follow-up in patients with COPD led to lower rates of readmissions at 90 days, while patients with CHF saw lower 90-day mortality.

Women show significantly lower risk of first, recurrent life-threatening VTA events than men, while it is more pronounced in patients with NICM.

Rivaroxaban monotherapy was associated with a 38% lower risk of total cardiovascular and bleeding events.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

Both exogenous hyperthyroidism and exogenous hypothyroidism were associated with increased risk of cardiovascular mortality.

Aortic sclerosis, trace or mild aortic regurgitation, and mild mitral regurgitation each had significant associations with CV risk.

The study authors used data from Medicare beneficiaries who survived a heart attack between 1995 and 2019.

Investigators observed no reduction in readmission or mortality in a remote monitoring program with incentives for patients previously hospitalized for HF.

The rate of long-term survival after 10 years in patients surviving the initial hospital stay after OHCA was between 62% and 64%.

Data show 7 risk factors, many potentially modifiable, accounted for 85% of the risk of first AMI in young women and men.

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.